APS Stock Overview
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Aptose Biosciences Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$2.24 |
52 Week High | CA$13.35 |
52 Week Low | CA$1.85 |
Beta | 1.44 |
1 Month Change | -12.84% |
3 Month Change | -33.13% |
1 Year Change | -82.22% |
3 Year Change | -98.01% |
5 Year Change | -94.23% |
Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Here's Why We're Watching Aptose Biosciences' (TSE:APS) Cash Burn Situation
Mar 26We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate
Dec 08We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate
Aug 05We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully
Apr 02Companies Like Aptose Biosciences (TSE:APS) Are In A Position To Invest In Growth
Sep 30Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling
Feb 07Is Aptose Biosciences Inc.'s (TSE:APS) Shareholder Ownership Skewed Towards Insiders?
Jan 03We're Not Very Worried About Aptose Biosciences' (TSE:APS) Cash Burn Rate
Nov 29Jotin Marango Is The Senior VP & Chief Business Officer of Aptose Biosciences Inc. (TSE:APS) And They Just Sold 26% Of Their Shares
Jul 11Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling
Jun 27Shareholder Returns
APS | CA Biotechs | CA Market | |
---|---|---|---|
7D | 6.2% | 1.4% | 0.4% |
1Y | -82.2% | -26.0% | 9.0% |
Return vs Industry: APS underperformed the Canadian Biotechs industry which returned -26% over the past year.
Return vs Market: APS underperformed the Canadian Market which returned 9% over the past year.
Price Volatility
APS volatility | |
---|---|
APS Average Weekly Movement | 9.0% |
Biotechs Industry Average Movement | 12.4% |
Market Average Movement | 8.5% |
10% most volatile stocks in CA Market | 18.4% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: APS's share price has been volatile over the past 3 months.
Volatility Over Time: APS's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1986 | 36 | William Rice | https://www.aptose.com |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin’s lymphomas, as well as AML and HR MDS.
Aptose Biosciences Inc. Fundamentals Summary
APS fundamental statistics | |
---|---|
Market cap | CA$32.22m |
Earnings (TTM) | -CA$69.36m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs APS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
APS income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$51.21m |
Earnings | -US$51.21m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.26 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did APS perform over the long term?
See historical performance and comparison